A Study of CM310 in Subjects With Moderate to Severe Asthma

Moderate to Severe Asthma Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Moderate to Severe Asthma

Status Recruiting

Clinical Trial Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05761028
Study type	Interventional
Source	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact	Wang Wenjuan
Phone	010-63942533
Email	wangwenjuan01@cspc.cn
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	April 28, 2023
Completion date	May 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03556683` - Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics	N/A
Recruiting	`NCT05774340` - A Study of CM326 in Subjects With Moderate to Severe Asthma	Phase 2
Recruiting	`NCT05851443` - A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma	Phase 2
Recruiting	`NCT06385236` - Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping	Phase 4
Completed	`NCT05062759` - Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma	Phase 3
Completed	`NCT04307173` - Study of Multiple Ascending Dose of KBL693 in Healthy Participants	Phase 1